Provided by Tiger Fintech (Singapore) Pte. Ltd.

Karyopharm Therapeutics

6.42
+0.28004.56%
Post-market: 6.420.00000.00%16:13 EDT
Volume:87.31K
Turnover:546.05K
Market Cap:54.03M
PE:-0.46
High:6.56
Open:6.07
Low:6.06
Close:6.14
Loading ...

Karyopharm price target raised to $5 from $4 at Piper Sandler

TIPRANKS
·
06 Nov 2024

RBC Capital Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)

TIPRANKS
·
06 Nov 2024

Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
06 Nov 2024

Karyopharm Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
06 Nov 2024

Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ...

GuruFocus.com
·
06 Nov 2024

Karyopharm Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
06 Nov 2024

Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings

TIPRANKS
·
06 Nov 2024

Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript

Motley Fool Transcribing
·
06 Nov 2024

Karyopharm Therapeutics: Strong Demand and Strategic Initiatives Justify Buy Rating

TIPRANKS
·
06 Nov 2024

Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
05 Nov 2024

Karyopharm Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
05 Nov 2024

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Benzinga
·
05 Nov 2024

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

Benzinga
·
05 Nov 2024

Karyopharm Therapeutics Inc Q3 Shr View $-0.26, REV View $37.8 Mln -- Lseg Ibes Data

THOMSON REUTERS
·
05 Nov 2024

Karyopharm Therapeutics Inc: Qtrly Loss per Shr $0.26

THOMSON REUTERS
·
05 Nov 2024

Karyopharm Therapeutics Inc: Qtrly REV $38.8 Mln

THOMSON REUTERS
·
05 Nov 2024